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The Shc family adaptor p66Shc acts as a negative regulator of prolifer-ative and survival signals triggered by the B-cell receptor and, byenhancing the production of reactive oxygen species, promotes
oxidative stress-dependent apoptosis. Additionally, p66Shc controls the
expression and function of chemokine receptors that regulate lymphocyte
traffic. Chronic lymphocytic leukemia cells have a p66Shc expression defect
which contributes to their extended survival and correlates with poor prog-
nosis. We analyzed the impact of p66Shc ablation on disease severity and
progression in the Eμ-TCL1 mouse model of chronic lymphocytic
leukemia. We showed that Eμ-TCL1/p66Shc-/- mice developed an aggres-
sive disease that had an earlier onset, occurred at a higher incidence and led
to earlier death compared to that in Eμ-TCL1 mice. Eμ-TCL1/p66Shc-/- mice
displayed substantial leukemic cell accumulation in both nodal and extra -
nodal sites. The target organ selectivity correlated with upregulation of
chemokine receptors whose ligands are expressed therein. This also applied
to chronic lymphocytic leukemia cells, where chemokine receptor expres-
sion and extent of organ infiltration were found to correlate inversely with
these cells’ level of p66Shc expression. p66Shc expression declined with dis-
ease progression in Eμ-TCL1 mice and could be restored by treatment with
the Bruton tyrosine kinase inhibitor ibrutinib. Our results highlight p66Shc
deficiency as an important factor in the progression and severity of chronic
lymphocytic leukemia and underscore p66Shc expression as a relevant ther-
apeutic target. 
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ABSTRACT
Introduction
Chronic lymphocytic leukemia (CLL) is characterized by the accumulation of
long-lived mature CD5+ B cells in peripheral blood, bone marrow and secondary
lymphoid organs.1 Leukemic cell survival is associated with defective apoptosis2
and, moreover, is promoted by stromal cell-derived chemokines during their transit
through secondary lymphoid organs,3 where they also undergo proliferation within
pseudofollicles.1 Imbalanced expression of chemokine receptors regulating homing
to (CCR7, CXCR4, CXCR5) and egress from (S1PR1) secondary lymphoid organs
concurs to retain CLL cells in the lymphoid niche.3
The adaptor p66Shc participates in signaling pathways linking oxidative stress to
apoptosis.4 p66Shc promotes the production of reactive oxygen species (ROS) by
interrupting the mitochondrial respiratory chain through cytochrome c binding and
oxidation, causing activation of the apoptotic cascade. Additionally, it negatively
regulates B-cell survival by modulating the expression of
several Bcl-2 family members and inhibiting the activation
of the pro-survival kinase Akt.5,6 p66Shc also participates
in B-cell trafficking by controlling CCR7, CXCR4 and
S1PR1 surface expression both transcriptionally and post-
translationally.7,8 Moreover, p66Shc attenuates CXCR4 and
CXCR5 signaling.9 CLL cells have a defect in the expres-
sion of p66Shc6 and its transcription factor STAT410 which
is causal to their extended survival,6,7,11 suggesting a link
between p66Shc deficiency and the pathogenesis of CLL.
Overexpression of TCL1 driven by the IgM heavy chain
enhancer (Eμ-TCL1) in mice results in the development of
a B-cell leukemia that recapitulates aggressive CLL.12 Here
we have addressed the effect of p66Shc deficiency on the
onset, development and outcome of CLL by generating a
Eμ-TCL1/p66Shc-/- mouse. We showed that p66Shc dele-
tion in Eμ-TCL1 mice resulted in accelerated leukemogen-
esis and enhanced disease aggressiveness, with enhanced
nodal and extranodal infiltration. Our data provide direct
evidence that p66Shc deficiency concurs to CLL pathogen-
esis and highlight p66Shc expression as a relevant disease
target.  
Methods
A detailed description of the methods is available in the Online
Supplementary Data file.
Mice
Eμ-TCL112,13 and p66Shc-/- C57BL/6J (C57/p66-/-)14 mice were
crossed to generate Eμ-TCL1/p66Shc-/- mice: the screening strategy
is illustrated in Online Supplementary Figures S1 and S2. C57BL/6J
and C57/p66-/- mice were used as controls. Mice with ≥10%
peripheral blood CD5+CD19+ cells were considered to have devel-
oped leukemia. Overt leukemia was defined as reported else-
where.13
Cell lines, patients and healthy donors
Transfectants generated using the CLL-derived B-cell line
MEC115 and expressing human full-length p66Shc or the
p66ShcQQ mutant were described previously.8 p66shc silencing in
an Epstein-Barr virus (EBV) B-cell line was performed as described
elsewhere.10 Peripheral blood samples were collected from 157
treatment-naïve CLL patients and five CLL patients subjected to
pharmacological treatments (Online Supplementary Table S1). B cells
from 15 buffy coats were used as healthy population controls. B
cells were purified and transfected as described previously.8
Immunophenotyping of leukemic cells
Single-cell suspensions from mouse peripheral blood, peritoneal
wash, spleen, bone marrow, lymph nodes, liver and lung were
depleted of erythrocytes by hypotonic lysis and incubated with
mouse Fc-Block for 15 min at 4°C. Murine leukemic cells and B
cells purified from CLL patients and healthy donors were stained
(antibodies and reagents listed in Online Supplementary Table S2)
and subjected to flow cytometry (Guava Easy Cyte cytometer,
Millipore).
RNA purification and polymerase chain reactions
Total RNA was extracted and retrotranscribed as described pre-
viously.8 Real-time polymerase chain reactions (PCR) (primers list-
ed in Online Supplementary Table S3) were performed using GoTaq
Long PCR Master Mix (Promega) and results were processed and
analyzed as described elsewhere.11
Cell treatment, apoptosis and reactive oxygen species
measurement, immunoblot and chemotaxis assays
Freshly isolated normal and leukemic mouse B cells were treat-
ed with 50 μM H2O2 for 24 h, 1 μM ibrutinib for 48 h, or 35 μM
fludarabine phosphate for 16 h. Dimethylsulfoxide was used as a
control. Apoptosis was measured by flow cytometry on FITC-
labeled annexin-V -stained CD5+IgM+ cells. Intracellular ROS were
measured by flow cytometry in cells labeled for 30 min at 37°C
with 5 μM CM-H2DCFDA.8
Immunoblots and chemotaxis assays (antibodies and
chemokines listed in Online Supplementary Table S2) were carried
out as reported previously.16
Histopathology and immunohistochemistry
Tissues, peripheral blood and peritoneal wash were collected
and processed as detailed in the Online Supplementary Methods. 
Statistical analyses
One-way analysis of variance (ANOVA) with a post-hoc Tukey
test was used for experiments in which multiple groups were
compared. Mann-Whitney rank-sum tests were performed to
determine the significance of differences between two groups.
Survival curves and medians were calculated within subgroups
with the Kaplan-Meier method. A log-rank test was used to com-
pare differences between estimated survival curves. Statistical
analyses were performed using GraphPad Software (La Jolla, CA,
USA). P values <0.05 were considered statistically significant.
Study approval
Experiments were approved by the Institutional Review Board
and the local Ethics Committee.
Results
p66Shc expression decreases during leukemia 
progression in tumoral cells from Eμ-TCL1 mice
CLL cells have a profound reduction in p66Shc expres-
sion, which is more severe in patients with an unfavorable
prognosis.6 As Eμ-TCL1 mice are a model of aggressive
CLL,17 we investigated whether the p66Shc defect in CLL
cells is recapitulated in leukemic Eμ-TCL1 cells. p66Shc
mRNA was quantified in splenic leukemic cells from Eμ-
TCL1 mice with overt leukemia (≥50% peripheral blood
CD5+CD19+ cells and a white blood cell count above the
normal range; see Online Supplementary Methods).13 The
analysis was extended to B1a cells from C57BL/6 mice, the
normal CD5+ B-cell counterpart,18 and to the two other
mature B-cell subsets, B1b and B2. While p66Shc was
expressed at comparable levels in all normal B-cell subsets,
tumoral B cells from mice with advanced disease expressed
less p66Shc compared to normal B1a cells (Figure 1A).
Interestingly, B1a cells from Eμ-TCL1 mice with milder
disease (~20% peripheral blood CD5+CD19+ cells) had
intermediate levels of p66Shc (Figure 1B,C), indicating that
p66Shc expression declines during disease progression, as
further supported by a >78% inverse correlation between
p66Shc mRNA levels in CD5+CD19+ cells and the percent-
age of leukemic cells in peripheral blood from the same
mouse (Figure 1D). STAT4, a key transcription factor for
p66Shc that is defective in CLL cells,10 was also downregu-
lated in Eμ-TCL1 mice (Figure 1C,E).
The p66Shc expression defect in CLL cells can be res-
cued by in vitro or in vivo treatment with the Btk inhibitor
ibrutinib, used for CLL treatment.7,19 As for human CLL
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cells, p66Shc expression increased in splenic leukemic
cells from Eμ-TCL1 sick mice treated with 1 μM ibrutinib
for 48 h, concomitant with increased STAT4 expression
(Figure 1F,G) supporting the notion that the therapeutic
effects of ibrutinib are associated with its STAT4/p66Shc-
elevating activity.
p66Shc deficiency accelerates leukemogenesis 
in Eμ-TCL1 mice
Our results suggest that the p66Shc defect observed in
leukemic CLL and Eμ-TCL1 cells may be implicated in dis-
ease pathogenesis. To test this hypothesis, we transferred
the p66shc-/- allele into Eμ-TCL1 mice (Online
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Figure 1. p66Shc expression decreases during leukemia progression in tumoral cells from Eμ-TCL1 mice and can be restored by ibrutinib treatment. (A)
Quantitative real-time polymerase chain reaction (qRT-PCR) analysis of p66Shc mRNA in B1a, B1b, B2 and total mature B lymphocytes purified from four wildtype
(WT) mice and in leukemic cells purified from five Eμ-TCL1 sick mice. The relative gene transcript abundance was determined on triplicate samples using the DDCt
method and normalized to GAPDH. (B, E). qRT-PCR analysis of p66Shc (B) and STAT4 (E) mRNA in B lymphocytes purified from five WT mice and in leukemic cells
purified from Eμ-TCL1 mice with mild (~20% CD5+CD19+ cells in peripheral blood) (n=6) or overt leukemia (≥50% CD5+CD19+ cells and white cell count
>10.7x106/mL in peripheral blood) (n=5). The relative gene transcript abundance was determined on triplicate samples using the DDCt method. (C) Immunoblot
analysis with anti-Shc and anti-STAT4 antibodies of postnuclear supernatants of leukemic cells purified from either WT (n=3) or Eμ-TCL1 mice with mild (n=3) or
overt leukemia (n=3). The stripped filters were reprobed with anti-actin antibodies. (D) Correlation between the percentages of CD5+CD19+ cells and the mRNA levels
of p66Shc in peripheral blood samples obtained from Eμ-TCL1 mice at different disease stages (n=12). (F) qRT-PCR analysis of p66Shc (left) and STAT4 (right) mRNA
in leukemic cells purified from spleens of Eμ-TCL1 sick mice (n=4) incubated for 48 h with either dimethylsulfoxide (DMSO) (absolute cell viability: 88.4 ± 3.2% of
annexin V-/propidium iodide- cells) or 1 μM ibrutinib (absolute cell viability: 84.9 ± 2.9% of annexin V-/propidium iodide- cells). The relative gene transcript abundance
was determined on triplicate samples using the DDCt method. (G) Immunoblot analysis with anti-Shc and anti-STAT4 antibodies of postnuclear supernatants of
leukemic cells purified from spleens of Eμ-TCL1 sick mice (n=3) incubated for 48 h with either DMSO or 1 μM ibrutinib. The stripped filters were reprobed with anti-
actin antibodies. Mean ± standard deviation. One-way analysis of variance (ANOVA), multiple comparisons. ****P≤0.0001; ***P≤0.001; **P≤0.01; *P≤0.05
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Supplementary Figure S1A,B).12 As expected, Eμ-
TCL1/p66Shc-/- B cells did not express p66Shc (Online
Supplementary Figure S1C,D) while expressing wildtype
p53, similar to Eμ-TCL1 cells (Online Supplementary
Methods and Online Supplementary Table S3).20 Eμ-
TCL1/p66Shc-/- mice developed a CLL-like disease similar
to that occurring in Eμ-TCL1 mice. A large lymphocyte
population, associated with the characteristic Gumprecht
shadows, was evident in peripheral blood smears from
sick mice (Online Supplementary Figure S1E). Flow cytomet-
ric analysis of peripheral blood samples from 6- and 9-
month old mice revealed a discrete population of CD5+ B
cells, which is the hallmark of disease development in Eμ-
TCL1 mice (Online Supplementary Figures S1F and S2).12
Similar to Eμ-TCL1 mice, leukemic Eμ-TCL1/p66Shc-/-
mice eventually became visibly ill, showing labored
breathing and splenomegaly (Online Supplementary Figure
S1G and Online Supplementary Table S4) that necessitated
euthanasia.
To address the impact of p66Shc deficiency on disease
onset and progression, we followed leukemia develop-
ment in 87 Eμ-TCL1 and 134 Eμ-TCL1/p66Shc-/- mice by
immunophenotyping monthly peripheral blood samples.
Eμ-TCL1/p66Shc-/- mice showed higher white blood cell
counts and higher CD5+CD19+ cell percentages in periph-
eral blood compared to those in Eμ-TCL1 mice (Figure
2A,B; Online Supplementary Figure S1G). Moreover disease
progression, assessed as rate of increase in the percentage
of CD5+CD19+ cells, was faster in Eμ-TCL1/p66Shc-/- mice
(Figure 2C).
Disease incidence, defined as the percentage of sick
mice (>10% peripheral blood CD5+CD19+ cells vs. ~5% in
healthy C57BL/J6 mice) (Online Supplementary Figure S3) at
defined time points, was significantly higher in Eμ-
TCL1/p66Shc-/- mice than in Eμ-TCL1 mice (Figure 2D).
Moreover, p66Shc deficiency led to an earlier onset of dis-
ease, which was detected ~2 months earlier in Eμ-
TCL1/p66Shc-/- mice (Figure 2D) and resulted in a shorter
lifespan (Figure 2E). Hence p66Shc deficiency in Eμ-TCL1
mice accelerates disease onset and development as well as
its progression to an aggressive presentation. 
p66Shc deficiency enhances leukemic cell 
chemoresistance 
Consistent with the ability of p66Shc to modulate the
expression of pro- and anti-apoptotic Bcl-2 family mem-
bers,6 leukemic Eμ-TCL1/p66Shc-/- cells expressed higher
and lower levels of Bcl-2 and Bax, respectively, compared
to levels in their Eμ-TCL1 counterparts (Figure 3A,B). At
variance, Mcl-1 expression was comparable (Online
Supplementary Figure S4). Accordingly, leukemic cells from
sick Eμ-TCL1/p66Shc-/- mice were more resistant to flu-
darabine treatment, also when co-cultured with OP9 stro-
mal cells to simulate the pro-survival stromal microenvi-
ronment (Figure 3C). Hence p66Shc deficiency in Eμ-
TCL1 leukemic cells promotes these cells’ survival, which
likely contributes to the faster disease development and
unfavorable outcome in Eμ-TCL1/p66Shc-/- mice. This is
supported by the higher sensitivity to fludarabine of
leukemic cells from Eμ-TCL1 mice with milder disease
(<35% peripheral blood CD5+CD19+ cells) compared to
leukemic cells from mice at later disease stages (≥35%
peripheral blood CD5+CD19+ cells) (Figure 3D), which
may be accounted for, at least in part, by their higher
residual p66Shc expression (Figure 1B,C). Consistent with
this notion, tumoral Eμ-TCL1/p66Shc-/- cells were less sen-
sitive to fludarabine treatment, independently of disease
stage (Figure 3D). Hence the reduction of p66Shc expres-
sion in Eμ-TCL1 mice during disease development con-
tributes to the decreased chemosensitivity of leukemic
cells. 
p66Shc deficiency in Eμ-TCL1 mice is associated 
with nodal and extranodal leukemic cell accumulation
Leukemic cells accumulate in the peritoneal cavity of Eμ-
TCL1 mice at early stages of disease, subsequently coloniz-
ing spleen, bone marrow and lymph nodes as well as extra-
nodal sites.12 p66Shc modulates the surface levels of recep-
tors that regulate homing to and egress from secondary
lymphoid organs,8,7 suggesting that its deficiency might con-
tribute to leukemic cell accumulation in secondary lym-
phoid organs and infiltration into non-lymphoid organs.
The extent of organ infiltration by leukemic cells was meas-
ured in spleen, bone marrow and lymph nodes from Eμ-
TCL1 and Eμ-TCL1/p66Shc-/- mice with ~60% leukemic
cells in peripheral blood. The analysis was extended to liver
and lung, as infiltration in these organs has been document-
ed in CLL,21,22 as well as to the peritoneal infiltrate. 
Flow cytometric analysis of CD5+CD19+ cells revealed
higher percentages of leukemic cells in lymph nodes of
Eμ-TCL1/p66Shc-/- mice than in those of Eμ-TCL1 mice
(Figure 4A). This was confirmed by hematoxylin & eosin
staining and immunohistochemical analysis of the same
organs, which highlighted massive lymph node infiltra-
tion of Eμ-TCL1/p66Shc-/- mice by small lymphoid-like
B220+ cells (Figure 4A). At variance, leukemic cell accumu-
lation in spleen and bone marrow was comparable (Online
Supplementary Figure S5 and Online Supplementary Table
S4), suggesting that Eμ-TCL1/p66Shc-/- tumoral cells show
organ selectivity. 
Leukemic cell infiltrates in the liver and lung were found
to be more substantial in Eμ-TCL1/p66Shc-/- mice than in
Eμ-TCL1 mice and were frequently associated with loss of
organ architecture (Figure 4B,C). Increased peritoneal
leukemic cell accumulation was also observed in Eμ-
TCL1/p66Shc-/- mice (Figure 4D). Interestingly, flow cyto-
metric analysis of the proliferation marker Ki-67 revealed
a higher proliferation rate of leukemic Eμ-TCL1/p66Shc-/-
cells in lymph nodes, liver and lung compared to their Eμ-
TCL1 counterparts (Online Supplementary Figure S6), con-
sistent with the anti-mitogenic function of p66Shc.23
Increased colonization of nodal and extranodal sites
by Eμ-TCL1/p66Shc-/- cells is associated with higher
expression of homing receptors
The chemokine receptors CXCR4 and CCR7 contribute
to the pathogenesis of CLL by modulating leukemic B-cell
homing to secondary lymphoid organs and bone mar-
row.3,24,25 p66Shc modulates surface expression of homing
and egress receptors both transcriptionally and post-trans-
lationally in normal and CLL B cells,7,8 suggesting that the
increased colonizing ability of leukemic Eμ-TCL1/p66Shc-/-
cells may be caused by imbalanced expression of these
receptors. Splenic leukemic cells from Eμ-TCL1 and Eμ-
TCL1/p66Shc-/- mice with overt leukemia were analyzed
by quantitative real-time PCR and flow cytometry for
expression of chemokine receptors that regulate CLL cell
homing to and residency in lymphoid organs, namely
CXCR4, CCR7 and S1PR1. Splenic B cells from C57BL6/J
and C57BL6/J/p66Shc-/- mice were used as controls.
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Expression of CXCR4, which mainly guides B-cell homing
to the bone marrow,26 was comparable in leukemic cells
from both mouse strains (Figure 5A), accounting at least
in part for the comparable extent of tumoral cell infiltra-
tion in the spleen. Conversely, surface expression of
CCR7, the main lymph node B-cell homing receptor,27
was higher in Eμ-TCL1/p66Shc-/- cells (Figure 5B).
Expression of S1PR1, which controls B-cell egress from
secondary lymphoid organs,28 was strongly downregulat-
ed in Eμ-TCL1/p66Shc-/- compared to Eμ-TCL1 cells
(Figure 5C), in agreement with the causal relationship
between p66Shc and S1PR1 expression in CLL cells.8
Consistent with these results and the massive lymph node
colonization (Figure 4A), leukemic Eμ-TCL1/p66Shc-/- cell
chemotaxis towards the CCR7 ligand MIP-3β and the
S1PR1 ligand S1P was enhanced and suppressed, respec-
L. Patrussi et al.
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Figure 2. p66Shc deficiency accel-
erates leukemogenesis in Eμ-TCL1
mice. (A, B) Flow cytometric analy-
sis of the percentages (A) and white
blood cell (WBC) counts (B) of
CD5+CD19+ cells in peripheral blood
samples from either Eμ-TCL1
(n=87) or Eμ-TCL1/p66Shc-/-
(n=134) mice collected at the indi-
cated months. (C) Trend-lines calcu-
lated on the monthly average per-
centages of CD5+CD19+ cells in the
Eμ-TCL1 and Eμ-TCL1/p66Shc-/-
mice shown in (A). (D) Analysis of
the percentages of sick mice, calcu-
lated as the percentage of mice
with ≥10% CD5+CD19+ cells, calcu-
lated on the percentages of
CD5+CD19+ cells shown in (A). (E)
Log-rank survival analysis of the Eμ-
TCL1 or Eμ-TCL1/p66Shc-/- mice
shown in (A). Mean ± standard devi-
ation. Mann-Whitney rank sum test.
****P≤0.0001; ***P≤0.001;
**P≤0.01; ns: not significant.
A
B
C D
E
tively, compared to that of leukemic Eμ-TCL1 cells, as
assessed in transwell assays (Online Supplementary Figure
S7). Although surface and mRNA levels of CXCR4 were
similar in the two mouse strains, tumoral Eμ-
TCL1/p66Shc-/- cell chemotaxis towards the CXCR4 lig-
and CXCL12 was enhanced (Online Supplementary Figure
S7), consistent with the ability of p66Shc to negatively
regulate CXCR4-dependent signaling9 and CXCR4 recy-
cling7 in human B cells.
Lymphocyte homing to non-lymphoid organs is con-
trolled by G protein-coupled receptors. B-cell homing to
the liver is regulated by CCR1, CCR2, and CXCR3,
while CCR2, CCR5, and CXCR3 have been implicated in
B-cell homing to the lung.29-34 CCR1 and CCR5 mRNA
levels in leukemic cells were comparable in the two
mouse strains (Online Supplementary Figure S8).
Conversely, both surface and mRNA levels of CCR2 and
CXCR3 were higher in leukemic Eμ-TCL1/p66Shc-/- cells
p66shc deletion exacerbates leukemia in TCL1 mice
haematologica | 2019; 104(10) 2045
Figure 3. p66Shc deficiency in leukemic
cells results in enhanced chemoresis-
tance. (A) Quantitative real-time poly-
merase chain reaction analysis of Bcl-2
and Bax mRNA in leukemic cells purified
from either wildtype (WT) (n=7) or
p66Shc-/- (n=7) mice and from Eμ-TCL1
(n=10) or Eμ-TCL1/p66Shc-/- (n=12)
mice with overt leukemia. The relative
gene transcript abundance was deter-
mined on triplicate samples using the
DDCt method. (B) Immunoblot analysis
with anti-Bcl-2 (left) and anti-Bax (right)
antibodies of postnuclear supernatants
of leukemic cells purified from either WT
(n=3) or p66Shc-/- (n=3) mice and from
Eμ-TCL1 (n=3) or Eμ-TCL1/p66Shc-/-
(n=3) mice with overt leukemia. The
stripped filters were reprobed with anti-
actin antibodies. (C) Flow cytometric
analysis of the percentages of annexin
V+CD5+IgM+ cells in peripheral blood
from either WT (n=9) or p66Shc-/- (n=8)
mice and from Eμ-TCL1 (n=20) or Eμ-
TCL1/p66Shc-/- (n=22) mice. Samples
were treated with either dimethylsulfox-
ide (DMSO) or 35 μM fludarabine (flu)
for 16 h at 37°C. (D) Flow cytometric
analysis of the percentages of annexin
V+CD5+IgM+ cells in peripheral blood
from either Eμ-TCL1 (n=20) or Eμ-
TCL1/p66Shc-/- (n=22) mice with <35%
(black boxes) or ≥35% (gray boxes)
CD5+CD19+ leukemic cells in peripheral
blood, treated with either DMSO or 35
µM fludarabine for 16 h at 37°C. Mean
± standard deviation. One-way analysis
of variance (ANOVA), multiple compar-
isons. ****P≤0.0001; ***P≤0.001;
**P≤0.01; *P≤0.05
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than in Eμ-TCL1 cells (Figure 5D,E). Consistent with
these results and their enhanced liver and lung coloniza-
tion (Figure 4B,C), chemotaxis towards the respective
chemokines was enhanced in leukemic Eμ-TCL1/p66Shc-
/- cells compared to leukemic Eμ-TCL1 cells (Online
Supplementary Figure S7). Of note, similar effects, albeit
less pronounced, were observed when mRNA and sur-
face levels of these receptors, and the chemotactic
responses thereof, were analyzed in B cells from
C57BL6/J and C57BL6/J/p66Shc-/- mice (Figure 5 and
Online Supplementary Figure S7), further supporting the
central role of p66Shc in modulating expression of these
receptors. Collectively, these results suggest that the
more efficient colonization of and accumulation in extra-
nodal sites by p66Shc-/- leukemic cells can be accounted
for, at least in part, by the ability of p66Shc to modulate
the expression of chemokine receptors that guide the
cells’ homing to those sites. 
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Figure 4. Nodal and extran-
odal accumulation of
leukemic cells lacking
p66Shc. (A-D) (Left) Flow cyto-
metric analysis of the percent-
ages of CD5+CD19+ cells in
lymph nodes (A), liver (B), lung
(C) and peritoneal wash (D)
from either Eμ-TCL1 (n=15) or
Eμ-TCL1/p66Shc-/- (n=15)
mice with overt leukemia.
(Right) Hematoxylin & eosin
staining (upper panels) and
immunohistochemical analysis
of B220 (lower panels) in
lymph nodes (A), liver (B), lung
(C) and peritoneal wash (D)
from either Eμ-TCL1 (n=5) or
Eμ-TCL1/p66Shc-/- (n=10) with
overt leukemia.
(Immunoperoxidase staining;
original magnification, 5x, 10x
and 20x). Mean ± standard
deviation. Mann-Whitney rank
sum test. ****P≤0.0001;
***P≤0.001; **P≤0.01.
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Figure 5. p66Shc deficiency in leukemic cells results in enhanced expression of homing receptors and reduced expression of the egress receptor S1PR1. (A-E)
Quantitative real-time polymerase chain reaction analysis of the mRNA levels (left) and flow cytometric analysis of surface expression (right) of CXCR4 (A), CCR7 (B),
S1PR1 (C), CCR2 (D) and CXCR3 (E) in CD5+CD19+ cells purified from either wildtype (WT) (n=16) or p66Shc-/- (n=15) mice (B1a cells) and from Eμ-TCL1 (n≥16) or
Eμ-TCL1/p66Shc-/- (n≥16) mice with overt leukemia. The relative gene transcript abundance was determined on triplicate samples using the DDCt method.
Representative flow cytometric plots of the indicated stains are shown on the right. Chemotaxis toward the respective chemokines is shown in Online Supplementary
Figure S6. Mean ± standard deviation. One-way analysis of variance (ANOVA), multiple comparisons. ****P≤0.0001; ***P≤0.001; **P≤0.01; *P≤0.05.
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Reconstitution of p66Shc in chronic lymphocytic
leukemia cells normalizes their CCR2 and CXCR3
expression 
We translated these results to human CLL cells, in
which a drastic reduction in p66Shc mRNA was observed
compared to levels in healthy donor B cells, with lower
residual levels in patients with unmutated IGHV (UM-
CLL), who develop aggressive disease,35 compared to
patients with mutated IGHV (M-CLL) (Figure 6A,B).6 No
correlation with other genetic markers of CLL, namely
13q deletion or TP53 deletion/mutation, was observed
(Online Supplementary Figure S9A,B).
We investigated whether the residual levels of p66Shc in
CLL cells could be correlated with the expression of the
trafficking receptors found to be modulated by p66Shc
deficiency in Eμ-TCL1 leukemic cells. As reported,8 sur-
face and mRNA levels of CCR7 and S1PR1 correlated
inversely and directly, respectively, with p66Shc expres-
sion in CLL cells from the patients included in this study
(Figure 6C,D and Online Supplementary Figure S10A,B).
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Figure 6. p66Shc deficiency is
associated with abnormal expres-
sion of chemokine receptors and
lymphadenopathy in human
chronic lymphocytic leukemia. (A,
B) Quantitative real-time poly-
merase chain reaction (qRT-PCR)
analysis of p66Shc mRNA in B
cells purified from either healthy
donors (HD) (n=12) or patients
with chronic lymphocytic leukemia
(CLL) (n=157) (A), or B cells puri-
fied from CLL patients, grouped
into those with mutated CLL (M-
CLL) (n=67) or unmutated CLL
(UM-CLL) (n=64) (B). (C-G)
Correlation between mRNA levels
of p66Shc and surface expression
levels of CCR7 (C), S1PR1 (D),
CXCR4 (E), CCR2 (F) and CXCR3
(G) in B cells purified from CLL
patients (n≤89). (H) qRT-PCR
analysis of CCR2 (left) and CXCR3
(right) mRNA in purified CLL B
cells (n=6), nucleofected with
either empty vector (CLL vect) or
an expression construct encoding
p66Shc (CLL p66). The relative
gene transcript abundance was
determined on triplicate samples
using the DDCt method. Mean ±
standard deviation. Mann-Whitney
rank sum test. ***P≤0.001" to
"****P≤0.0001; ***P≤0.001".
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Consistent with our finding that the upregulation of sur-
face CXCR4 in CLL cells is mainly controlled post-transla-
tionally,11 no correlation was observed between the
mRNA levels of p66Shc and CXCR4 (Figure 6E and Online
Supplementary Figure S10C).
The analysis was extended to CCR2 and CXCR3,
which were selectively overexpressed in UM-CLL cells
(Online Supplementary Figure S9C,D). Similar to CCR7,
expression of these receptors was inversely correlated
with that of p66Shc (Figure 6F,G and Online Supplementary
Figure S10D,E), suggesting that p66Shc may negatively
modulate their expression. p66Shc reconstitution in CLL
cells did indeed result in a decrease in CCR2 and CXCR3
mRNA (Figure 6H and Online Supplementary Figure S10F).
Interestingly, infiltration of both nodal and extranodal
areas, assessed by the number and size (cm) of infiltrated
lymph nodes and the presence of spleen and/or liver
enlargement, was significantly greater in patients whose
leukemic cells had p66Shc mRNA levels below an arbi-
trarily set threshold (0.24, corresponding to the mean
DDCt p66Shc mRNA of all CLL patients) (Online
Supplementary Figure S11 and Table 1). These data provide
evidence of a correlation of the severity of the p66Shc
expression defect in CLL cells with their ability to infil-
trate both nodal and extranodal districts, strongly sup-
porting a role for p66Shc deficiency in disease presenta-
tion. Of note, p66Shc expression was enhanced in CLL
patients showing a significant response to second-line
ibrutinib treatment but not in CLL patients who failed to
respond to ibrutinib therapy (Table 1 and Online
Supplementary Table S1), suggesting that the response of
CLL patients to therapeutic regimens results, at least in
part, from the ability of leukemic cells to restore p66Shc
expression.
Modulation of CCR2 and CXCR3 expression by p66Shc
is mediated by its pro-oxidant activity
p66Shc has a ROS-elevating activity that depends on its
ability to interact with cytochrome c and interrupt the
respiratory chain.4 We quantified homeostatic ROS pro-
duction in CLL cells loaded with the cell-permeant probe
CM-H2DCFDA. ROS production was profoundly
decreased in CLL B cells compared to that in normal B
cells, with the lowest levels in UM-CLL patients (Figure
7A), consistent with their lowest p66Shc levels.6
Furthermore, we found a direct correlation between ROS
production and p66Shc expression in CLL cells (Figure
7B). These findings were recapitulated in CM-H2DCFDA-
loaded Eμ-TCL1 cells which, similar to CLL cells, express
low levels of p66Shc (Figure 1B) and in which ROS pro-
duction was lower than that in B cells from control
C57BL/6 mice (Figure 7C). ROS production was further
impaired in Eμ-TCL1/p66Shc-/- cells (Figure 7C), confirm-
ing the pro-oxidant activity of p66Shc.
Transcription of both ccr7 and s1pr1 is controlled in
opposite directions by the ROS-elevating activity of
p66Shc.8 To address the potential role of the pro-oxidant
function of p66Shc in the regulation of CCR2 and CXCR3
expression we used the CLL-derived human B-cell line
MEC1 stably transfected with a ROS-defective mutant
carrying a E→Q substitution at positions 132-133
(p66QQ), which disrupts cytochrome c binding (Figure
7D,E).8 The empty vector transfectant lacking p66Shc (ctr)
and a transfectant expressing the wildtype protein (p66)
were used as controls. Flow cytometric analysis of home-
ostatic ROS production in the CM-H2DCFDA-loaded
MEC1 transfectants showed enhanced ROS production
in p66Shc-expressing cells, but not in cells expressing
p66ShcQQ, compared to control cells (Figure 7F). 
Mitochondrial redox signaling and apoptosis are also
modulated by p53,36 which is mutated in a large propor-
tion of CLL patients1 as well as in MEC1 cells.37 To rule
out a role for TP53 mutations in the enhanced ROS pro-
duction by p66Shc-expressing MEC1 cells, ROS were
measured in EBV-immortalized B cells, which express
wildtype p53,38 transiently depleted of p66Shc by short
interfering RNA-mediated knock-down. Similar to MEC1
cells, p66Shc deficiency in EBV-immortalized B cells
resulted in a lower intracellular ROS content and
enhanced CCR2 and CXCR3 expression (Online
Supplementary Figure S12), underscoring the specific con-
tribution of p66Shc to the ROS-dependent modulation of
these receptors.
Surface and mRNA expression of CCR2 and CXCR3
was next measured in all transfectants. The wildtype
p66Shc-expressing transfectant, but not the p66QQ
transfectant, had lower mRNA and surface levels of both
receptors compared to the levels in control cells (Figure
7G,I). Surface and mRNA expression of CCR2 and
CXCR3 was also decreased in MEC1 cells after treatment
with 50 μM H2O2, an exogenous ROS source (Figure 7H-
J), indicating that the ability of p66Shc to modulate
CCR2 and CXCR3 expression involves its ROS-elevating
activity.  
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Table 1. Pathological characteristics of patients with chronic lymphocytic
leukemia and p66Shc mRNA levels in their respective leukemic cells during
treatment.  
                                   DDCt p66Shc mRNA
                                                                  >0.24±0.7                  ≤ 0.24±0.7
                                                            “above threshold”       “below threshold”
N. of CLL patients                                                       30                                        34
N. of UM-CLL patients                                                6                                         19
% UM-CLL                                                                  20.00                                  55.88
N. of infiltrated lymph nodes                            0.67±0.23                          2.27±0.24
                                                                                                                                 (***P<0.001 below vs.
                                                                                                                                      above threshold)
% LN >1.5 cm                                                            53.33                                  88.23
% Spleen infiltration (> 13 cm)                           13.33                                  70.59
% Liver infiltration (> 1 cm under arch)            3.33                                   29.41
                                                           Patients responding      Patients “failing”
                                                                  to ibrutinib                    ibrutinib
Before CIT                                                               0.8±0.2                           0.14±0.06*
                                                                                                                                   (* P<0.05 “failing” vs.
                                                                                                                                    responding patients)
Follow-up CIT                                                          5.8±2.3                                 0.35
Before ibrutinib                                                     1.1±1.04                           0.12±0.08
Follow-up ibrutinib                                               26.1±6.9                         0.23±0.22**
                                                                                                                   (**P<0.01 “failing” vs.
                                                                                                                                    responding patients)
Patients with chronic lymphocytic leukemia (CLL) were grouped according to p66Shc mRNA
expression into either “above threshold” and “below threshold” (threshold 0.24, corresponding
to the mean DDCt p66Shc mRNA; n CLL=157), or according to response to ibrutinib into either
“responding” or “failing” based on International Working Group CLL response criteria.50 Mann-
Whitney rank sum test. ***P≤0.001; **P≤0.01; *P≤0.05. LN: lymph nodes; CLL: chronic lympho-
cytic leukemia; UM-CLL: unmutated CLL; CIT: chemo-immunotherapy.
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Figure 7. The pro-oxidant activity of p66Shc modulates CCR2 and CXCR3 expression. (A, C) Flow cytometric analysis of reactive oxygen species (ROS) production in
B cells purified from either healthy donors (HD, n=7) or patients with chronic lymphocytic leukemia (CLL) grouped according to whether they had mutated CLL (M-
CLL) (n=11) or unmutated CLL (UM-CLL) (n=9) (A) and in B1a cells from wildtype (C57BL/6, n=9) mice and from Eμ-TCL1 (n=13) or Eμ-TCL1/p66Shc-/- (n=12) sick
mice (C), loaded with CM-H2DCFDA. Data refer to duplicate samples from each patient/donor/mouse. (B) Correlation between mRNA levels of p66Shc and ROS pro-
duction in B cells purified from CLL patients (n=28). (D, E) Immunoblot analysis of Shc expression (D) and quantitative real-time polymerase chain reaction (qRT-
PCR) analysis of p66Shc mRNA (E) in MEC1 B cells stably transfected with empty vector (ctr) or an expression construct encoding either wildtype p66Shc (p66) or
the EE132/133QQ (p66QQ) mutant, and in B cells purified from healthy donors (HD) (n=3). A control anti-actin blot of the stripped filter is shown below. The migration
of molecular mass markers is indicated. The domain structure of p66Shc showing the localization of the amino acid residues substituted in the mutants is schema-
tized at the top of the panel. (F) Flow cytometric analysis of ROS production in the MEC1 B-cell transfectants and in B cells purified from healthy donors (B cell, n=5)
loaded with CM-H2DCFDA. Data refer to duplicate samples from five independent experiments. (G, I). Flow cytometric analysis (G) and qRT-PCR analysis of the mRNA
levels (I) of CCR2 (left) and CXCR3 (right) in MEC1 transfectants. Data refer to duplicate samples from five independent experiments. (H, J). Flow cytometric analysis
(H) and qRT-PCR analysis of the mRNA levels (J) of CCR2 and CXCR3 in MEC1 cells treated for 24 h with either dimethylsulfoxide (DMSO) or 50 μM H2O2. Data refer
to duplicate samples from four independent experiments. The relative gene transcript abundance was determined on triplicate samples using the ΔΔCt method.
Mean ± standard deviation. Mann-Whitney rank sum test. ****P≤0.0001; ***P≤0.001**P≤0.01; *P≤0.05. MFI: mean fluorescence intensity.
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Discussion
Here we used a genetic approach to specifically assess
the outcome of p66Shc deficiency on CLL cell survival and
disease onset and development. We showed that p66Shc
deletion in Eμ-TCL1 mice results in accelerated leukemo-
genesis and enhanced disease aggressiveness, with mas-
sive nodal and extranodal infiltration. The enhanced abili-
ty of leukemic p66Shc-/- cells to infiltrate organs was asso-
ciated with increased expression of chemokine receptors
that drive homing to the organs. p66Shc expression
declined with disease progression in Eμ-TCL1 cells, simi-
lar to human CLL. This defect could be restored by ibruti-
nib treatment which enhanced the cells’ chemosensitivity.
These results demonstrate in vivo that the p66Shc defect
found in CLL cells concurs to CLL pathogenesis. Of note,
p66Shc-/- mice spontaneously develop age-related autoim-
munity,5 a feature frequently associated with CLL.1
Interestingly, p66Shc downregulation in CLL B cells
induces the expression of the inhibitory molecule ILT3,39
suggesting that compensatory mechanisms might be oper-
ational to restrain CLL cell responses.
The negative impact of p66Shc deletion on disease pro-
gression and outcome in Eμ-TCL1 mice can be accounted
for, at least in part, by the extended survival and chemore-
sistance of leukemic cells, even when co-cultured with
stromal cells as a surrogate pro-survival microenviron-
ment. The p66Shc expression defect in CLL contributes to
this biological behavior. p66Shc deficiency does indeed
impinge on the Bcl-2 family balance in B cells, contributing
to the shift of CLL cells towards survival, which correlates
with chemoresistance and poor prognosis.40 The ROS-ele-
vating activity of p66Shc4,14 underlies this latter’s ability to
modulate the genes, several of which are redox-sensitive.41
The survival of CLL cells depends to a major extent on
their ability to home to the pro-survival microenvironment
of bone marrow and secondary lymphoid organs. This
process is orchestrated by homing receptors responding to
local chemokines and egress receptors responding to lymph
and blood S1P.3 p66Shc is a central part of this circuitry
which it affects by: (i) modulating CCR7 and S1PR1 expres-
sion in opposite directions in a ROS-dependent fashion;8 (ii)
modulating CCR7 and CXCR4 by slowing down their
endosomal recycling;7 and (iii) attenuating CXCR4 and
CXCR5 signaling by recruiting the phosphatases SHP-1 and
SHIP-1 close to the activated receptors.9 The p66Shc defect
in CLL cells has a major impact on these processes, resulting
in enhanced responses to the chemokines of the lymphoid
niche and impaired response to S1P.7,8 This imbalance is
expected to contribute to the lymphadenopathy and
chemoresistance observed in a significant proportion of
CLL patients, and indeed the levels of CCR7 are significant-
ly higher and those of S1PR1 lower in CLL patients with
clinical lymphadenopathy.8 We showed that the levels of
p66Shc in leukemic cells are inversely related to both the
number and size of infiltrated lymph nodes in CLL patients.
The results obtained in Eμ-TCL1/p66Shc-/- mice, showing
massive lymph node accumulation during disease progres-
sion, provide experimental evidence that p66Shc deficiency
promotes the nodal leukemic cell accumulation in CLL. 
p66Shc deficiency also results in a striking extranodal
accumulation of leukemic cells, with a preference for liver
and lung, the most frequent extranodal target sites in
CLL.21,22 The ROS-related ability of p66Shc to modulate
the expression and function of CCR2 and CXCR3, which
drive neoplastic B-cell homing to liver and lung where the
respective ligands are expressed,42,43 may account for the
enhanced ability of leukemic Eμ-TCL1/p66Shc-/- cells to
colonize these organs. Interestingly, CCR2 and CXCR3
are overexpressed in CLL cells (as shown in this study and
reported by Trentin et al.44 for CXCR3). We show that
p66Shc reconstitution in CLL cells reverts these abnormal-
ities, validating in human CLL our finding that p66Shc
deficiency contributes to CCR2 and CXCR3 overexpres-
sion in leukemic Eμ-TCL1/p66Shc-/- cells.
p66Shc expression declines during disease progression
in Eμ-TCL1 mice, until its almost complete loss in mice
with overt leukemia, paralleling the progressive decrease
in fludarabine sensitivity of tumoral cells documented pre-
viously.20 p66shc transcription is largely controlled in sever-
al primary and transformed cells, including T cells, by his-
tone deacetylation and cytosine methylation in a CpG
island within the promoter.45,46 Although methylation
increases in Eμ-TCL1 mice during disease development,47
it is unlikely that methylation of the p66shc promoter
caused its progressive silencing, as p66Shc expression is
not epigenetically silenced in B cells.6 Rather, in these cells
p66shc is transcriptionally regulated by STAT4, which is
defective in CLL cells.10 Interestingly, p66Shc can be
restored both in CLL cells7 and in leukemic Eμ-TCL1 cells
(Figure 1F,G) by treatment with ibrutinib, which also pro-
motes STAT4 expression in leukemic Eμ-TCL1 cells
(Figure 1F,G). Ibrutinib modulates the expression of genes
downstream of Btk in the BCR and CXCR4 pathways,48,49
which are implicated in CLL, suggesting that STAT4 and
its target p66Shc may be regulated through these path-
ways. While this remains to be established, considering
the pleiotropic role of p66Shc in B-cell survival and traf-
ficking our finding suggests that direct or indirect STAT4
agonists that enhance the activity of residual STAT4 in
CLL cells may normalize p66Shc expression and over-
come chemoresistance in CLL. Our finding that inter-
leukin-12, which activates STAT4, restores p66Shc expres-
sion in CLL cells10 supports this hypothesis. Collectively,
our findings underscore the pathological outcome of
p66Shc deficiency in CLL and highlight the chemokine
receptor network as a central target of its activity. 
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